RXRX 240816 8.00P (RXRX240816P8000) Stock Options, News & Quotes

0.55
-0.10-15.38%

15min DelayClose Jul 25 16:00 ET

0.65High0.40Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

MomentumPython1337

Jul 23 10:57

it's slowly but surely filling the gap

$Recursion Pharmaceuticals(RXRX.US)$ trying to fill that gap when they announced that filthy stock sale to raise funds

MomentumPython1337

Jul 15 07:12

up 16% since i said i have started buying this again

$Schrodinger(SDGR.US)$ i have been saying this for days and weeks now but if you're looking for a time to buy small caps now is the time it's still not too late these small caps have massive price gaps they need to fill they'll be forming giant cup and handles and many of them have been bottoming for the longest time while the mag7 were carrying the whole SPY & QQQ
they just needed a catalyst from rate cuts and this expectation is enough to tr...

BucceesNation

Jun 29 23:52

RXRX 10% shareholder ARK adds 2.7M shares (June27)

$Recursion Pharmaceuticals(RXRX.US)$

Mr Long Term

Jun 29 07:30

Columns Three AI stocks on the Edge of a Massive surge

Last week, Nvidia $NVIDIA(NVDA.US)$ briefly eclipsed Microsoft $Microsoft(MSFT.US)$ as the world’s most valuable company. The AI chip maker is now worth $3.3 trillion… or roughly the combined value of every residential property in the state of Florida. Shares trade for 50 times forward earnings.
That caused expected hand-wringing on Wall Street.
“We’re not necessarily at peak bubble levels,” said Jonathan Stubbs of Berenberg, a wealth management fi...

BucceesNation

Jun 28 13:20

Recursion Secondary Offering includes Funds for dozens of clinical trials as well as Acquisitions

$Recursion Pharmaceuticals(RXRX.US)$
prospectus of secondary offering resolves two key areas in 4-6 quarters with funds coveing potentially dozensof clinical trials as well as acquisitions.
In May, Recursion also stated that they have future partnerships as well as current partners whose trials include non-dilutive funding as these clical trials progress.
Increased my stake by 15%